Using stem cells to improve heart function in children with a specific heart condition
The Allogeneic Human Mesenchymal Stem Cell (MSCs) injection in Patients with Hypoplastic Left Heart Sydrome: A Phase IIb Clinical Trial (ELPIS)
This study is looking at whether special stem cells can help improve heart function in children with Hypoplastic Left Heart Syndrome who are having important heart surgery, and it will carefully track how well these cells work to support their recovery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10890089 on NIH RePORTER |
What this research studies
This research investigates the use of allogeneic human mesenchymal stem cells (MSCs) to enhance heart function in children diagnosed with Hypoplastic Left Heart Syndrome (HLHS) who are undergoing a critical surgical procedure. The study aims to assess the effectiveness of MSC injections by measuring improvements in right ventricular function through advanced cardiac imaging techniques. A dedicated Data Coordinating Center will oversee the coordination, administration, and data management of the trial, ensuring that all aspects of the study are conducted efficiently and safely. The trial will involve close monitoring and follow-up to evaluate the outcomes of the treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old who have been diagnosed with Hypoplastic Left Heart Syndrome and are scheduled for stage II heart surgery.
Not a fit: Patients with other congenital heart defects or those not undergoing the specified surgical procedure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart function and overall health outcomes for children with Hypoplastic Left Heart Syndrome.
How similar studies have performed: While the use of stem cells in cardiac applications is an emerging field, this specific approach in HLHS patients is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Lai, Dejian — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Lai, Dejian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.